CD70 and hematologic disorder: Recent evidence revealed that CAR T cells targeting CD70 could inhibit the growth of glioma (54), head and neck squamous cell carcinoma (55), and multiple solid tumors (56) as well as hematologic malignancies (57) in vitro and in vivo.